Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction

European Journal of Heart Failure

Volumn 8, Issue 4, 2006, Pages 409-419

  Ahmed, Ali ^a,b,c   Aban, Inmaculada B ^c   Weaver, Michael T ^a,c   Aronow, Wilbert S ^d   Fleg, Jerome L ^e  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Ejection fraction; Heart failure; Outcomes; Serum digoxin concentration; Women

Indexed keywords

DIGOXIN; PLACEBO;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

AGED; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CAUSE OF DEATH; CHRONIC DISEASE; DIGOXIN; FEMALE; HUMANS; MIDDLE AGED; PLACEBOS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 33744919004     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.10.002     Document Type: Article

References (47)

1. Rathore S.S., Wang Y., and Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347 (2002) 1403-1411
2. Rideout E. Digoxin increased risk of death in women, but not men, with heart failure. Evid Based Nurs 6 (2003) 80
3. Rathore S.S., and Krumholz H.M. Digoxin therapy for heart failure: safe for women?. Ital Heart J 4 (2003) 148-151
4. See S., and Bruno P. Digoxin increases mortality among women with congestive heart failure. J Fam Pract 52 106 (2003) 111
5. Rathore S.S., Curtis J.P., Wang Y., Bristow M.R., and Krumholz H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003) 871-878
6. Eichhorn E.J., and Gheorghiade M. Digoxin-new perspective on an old drug. N Engl J Med 347 (2002) 1394-1395
7. Hallberg P., Michaelsson K., and Melhus H. Digoxin for the treatment of heart failure. N Engl J Med 348 (2003) 661-663 author reply
8. Hudson M., and Pilote L. Digoxin for the treatment of heart failure. N Engl J Med 348 (2003) 661-663 author reply
9. Moulias S., Tigoulet F., and Meaume S. Digoxin for the treatment of heart failure. N Engl J Med 348 (2003) 661-663 author reply
10. Gheorghiade M., Adams Jr. K.F., and Colucci W.S. Digoxin in the management of cardiovascular disorders. Circulation 109 (2004) 2959-2964
11. The Digitalis Investigation Group. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials 17 (1996) 77-97
12. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
13. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
14. Ho K.K., Pinsky J.L., Kannel W.B., and Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22 (1993) 6A-13A
15. Senni M., Tribouilloy C.M., Rodeheffer R.J., Jacobsen S.J., Evans J.M., Bailey K.R., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98 (1998) 2282-2289
16. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35 (2000) 1628-1637
17. Ahmed A., Roseman J.M., Duxbury A.S., Allman R.M., and DeLong J.F. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J 144 (2002) 365-372
18. Collins J.F., Howell C.L., and Horney R.A. Determination of vital status at the end of the DIG trial. Control Clin Trials 24 (2003) 726-730
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
20. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
21. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
22. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
23. Curtis J.P., Sokol S.I., Wang Y., Rathore S.S., Ko D.T., Jadbabaie F., et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 42 (2003) 736-742
24. Rothwell P.M. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365 (2005) 176-186
25. Rothman K.J. The estimation of synergy or antagonism. Am J Epidemiol 103 (1976) 506-511
26. Hosmer D.W., and Lemeshow S. Confidence interval estimation of interaction. Epidemiology 3 (1992) 452-456
27. Matthews J.N., and Altman D.G. Interaction 3: how to examine heterogeneity. BMJ 313 (1996) 862
28. Sciacqua A., Scozzafava A., Pujia A., Maio R., Borrello F., Andreozzi F., et al. Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension. Eur Heart J (2005)
29. SPSS for Windows, Rel. 13 program]. SPSS Inc.; 2005.
30. Lindenfeld J., Krause-Steinrauf H., and Salerno J. Where are all the women with heart failure?. J Am Coll Cardiol 30 (1997) 1417-1419
31. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
32. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 49-57
33. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: executive summary a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 104 (2001) 2996-3007
34. Remme W.J., and Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560
35. Konstam M.A. "Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. J Card Fail 9 (2003) 1-3
36. Aronow W.S. Prevalence of appropriate and inappropriate indications for use of digoxin in older patients at the time of admission to a nursing home. J Am Geriatr Soc 44 (1996) 588-590
37. Ahmed A., Allman R.M., and DeLong J.F. Inappropriate use of digoxin in older hospitalized heart failure patients. J Gerontol A Biol Sci Med Sci 57 (2002) M138-M143
38. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., Reiss C.K., and Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33 (1999) 1948-1955
39. Varela-Roman A., Gonzalez-Juanatey J.R., Basante P., Trillo R., Garcia-Seara J., Martinez-Sande J.L., et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart 88 (2002) 249-254
40. Philbin E.F., Rocco Jr. T.A., Lindenmuth N.W., Ulrich K., and Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 109 (2000) 605-613
41. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
42. Hennekens C.H., and Buring J.E. Measures of disease frequency and association. In: Mayrent S.L. (Ed). Epidemiology in medicine (1987), Little Brown and Company, Boston/Toronto 55-98
43. Deubner D.C., Tyroler H.A., Cassel J.C., Hames C.G., and Becker C. Attributable risk, population attributable risk, and population attributable fraction of death associated with hypertension in a biracial population. Circulation 52 (1975) 901-908
44. Zhang J., and Yu K.F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280 (1998) 1690-1691
45. Kerzner R., Gage B.F., Freedland K.E., and Rich M.W. Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. Am Heart J 146 (2003) 286-290
46. Swedberg K., Olsson L.G., Charlesworth A., Cleland J., Hanrath P., Komajda M., et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J (2005)
47. Ahmed A., Thornton P., Perry G.J., Allman R.M., and DeLong J.F. Impact of atrial fibrillation on mortality and readmission in older adults hospitalized with heart failure. Eur J Heart Fail 6 (2004) 421-426